Research programme: herbal extract therapeutics - Dong-A ST

Drug Profile

Research programme: herbal extract therapeutics - Dong-A ST

Alternative Names: DA-9803; DA-9805; Herbal extracts - Dong-A ST; Herbal therapeutics - Dong-A ST

Latest Information Update: 22 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dong-A ST
  • Class Antidementias; Antiparkinsonians; Herbal medicines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Parkinson's disease

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 22 Jun 2017 Dong-A ST plans a phase II trial for Parkinson's disease in USA in July 2017 (NCT03189563)
  • 31 Mar 2017 US FDA approves IND application for DA 9805 in Parkinson's disease (Dong-A ST 1Q 2017 Performance Results filed on 28 April 2017)
  • 31 Dec 2014 Research programme: herbal extract therapeutics - Dong-A ST is available for licensing as of 31 Dec 2014. http://en.donga-st.com/Pass.da?viewPath=/b03/researchClinicalChallenge
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top